A phase I trial of the small molecule pan-bcl-2 inhibitor obatoclax (GX15–070) in combination with docetaxel in patients with relapsed non-small cell lung cancer (NSCLC)

Eric B. Haura,C. A. Williams,Alberto Chiappori,J Adams,Donald W. Northfelt,Shakun Malik,D. Van Echo,Martin J. Edelman,M S Berger

A phase I trial of the small molecule pan-bcl-2 inhibitor obatoclax (GX15–070) in combination with docetaxel in patients with relapsed non-small cell lung cancer (NSCLC)

2008

Eric B. Haura
C. A. Williams
Alberto Chiappori
J Adams
Donald W. Northfelt
Shakun Malik
D. Van Echo
Martin J. Edelman
M S Berger

19035 Background: Over expression of bcl-2 family proteins is common in NSCLC and the BH-3 mimetic obatoclax (O) induces apoptosis in a subset of NSCLC where it synergizes with cisplatin (Li et al....

Keywords:

Bcl-2 Inhibitor
Small molecule
non-small cell lung cancer (NSCLC)
Obatoclax
Oncology
Internal medicine
Docetaxel
Medicine
in patient
Apoptosis
Cisplatin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations